Endpoints News 生物医药· Lei Lei Wu·· 14 天前AI 评分25
Sarepta 停止 Elevidys 确认 III 期临床试验入组
Sarepta quits enrolling for confirmatory Phase 3 trial of Elevidys
AI 导读
Sarepta 停止 Duchenne 肌营养不良基因治疗药物 Elevidys 的 III 期临床试验入组,该试验旨在确认药物疗效。
正文
Sarepta Therapeutics won’t enroll more patients in the Phase 3 trial of its Duchenne muscular dystrophy gene therapy Elevidys, a test that was meant to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news